Scientists have long known that people carrying the APOE2 variant of the APOE gene tend to live longer and have a significantly lower risk of Alzheimer's disease. But the biological mechanism behind that protection has remained a mystery — until now.
A new study from the Buck Institute for Research on Aging, published in Aging Cell, reveals that APOE2 helps neurons protect their DNA from damage and resist cellular senescence, the damaged, poorly functioning cellular state that becomes more common with age and is believed to drive neurodegeneration.
"We've known for years that APOE2 carriers tend to live longer and have a lower risk of Alzheimer's, but the protective mechanism has been a black box," said senior author Lisa M. Ellerby, PhD, professor at the Buck Institute. "Our work shows that APOE2 neurons are better at preventing and repairing DNA damage, and they resist the cellular aging program that drives so much of late-life decline."
APOE exists in three common forms — APOE2, APOE3, and APOE4 — differing by only two amino acids. Yet their effects on brain health are dramatically different. APOE4 is the strongest known genetic risk factor for late-onset Alzheimer's. APOE2, by contrast, is protective.
The researchers used human induced pluripotent stem cells (iPSCs) engineered to differ only at the APOE locus, turning them into two types of neurons: inhibitory GABAergic and excitatory glutamatergic neurons.
APOE2 neurons accumulated significantly less DNA damage than those carrying APOE3 or APOE4. They also showed stronger activation of DNA repair pathways and greater resistance to senescence when exposed to radiation or chemotherapy drugs. Their nucleoli were smaller and nuclear architecture better preserved — both signs of healthier cellular aging.
Remarkably, when the researchers added recombinant APOE2 protein to APOE4 neurons, the cells showed reduced DNA damage after radiation — suggesting the protective effect may be transferable, not limited to those born with the variant.
Older mice engineered with the human APOE2 gene showed similar brain cell protection, with better-preserved heterochromatin and nuclear structure in the hippocampus.
"Until now, the APOE field has focused largely on lipid handling and amyloid-beta biology," said Ellerby. "By showing that APOE alleles also tune how neurons defend their genome, this study connects a major longevity gene to two of the most actively studied hallmarks of aging."
The findings open new therapeutic directions: drugs that improve DNA repair or remove senescent cells from the brain could potentially reproduce some of APOE2's natural benefits — particularly for the millions of APOE4 carriers at highest risk for Alzheimer's.
